{"disease":{"id":"gastric-cancer-gastroesophageal-junction-cancer","name":"gastric cancer gastroesophageal junction cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07431281","title":"Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":2130,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02872116","title":"Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2031,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT02538562","title":"Human Epidermal Growth Factor Receptor 2 (HER2) Advanced Gastric Epidemiology Study in Korea","phase":"","overall_status":"COMPLETED","enrollment_count":1695,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT04314401","title":"National Cancer Institute \"Cancer Moonshot Biobank\"","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1600,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03221426","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1007,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03170960","title":"Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":914,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT07392892","title":"A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":840,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT06093425","title":"Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":820,"lead_sponsor_name":"Suzhou Transcenta Therapeutics Co., Ltd.","has_results":false},{"nct_id":"NCT06585501","title":"A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China","phase":"","overall_status":"COMPLETED","enrollment_count":805,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT06791538","title":"Robotic Versus Laparoscopic Radical Surgery for Locally Advanced Gastric Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":740,"lead_sponsor_name":"Southwest Hospital, China","has_results":false},{"nct_id":"NCT04140526","title":"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":733,"lead_sponsor_name":"OncoC4, Inc.","has_results":false},{"nct_id":"NCT06731478","title":"Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":726,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT06786169","title":"The Relationship of Psychological Stress With Therapy Efficacy and Prognosis of Gastric Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06346392","title":"AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":572,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03175224","title":"APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":497,"lead_sponsor_name":"Apollomics Inc.","has_results":false},{"nct_id":"NCT01813253","title":"Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":400,"lead_sponsor_name":"Kuhnil Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05677490","title":"mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":382,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT05107674","title":"A Study of NX-1607 in Adults With Advanced Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":345,"lead_sponsor_name":"Nurix Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06293898","title":"Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":280,"lead_sponsor_name":"SystImmune Inc.","has_results":false},{"nct_id":"NCT06452329","title":"A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesophageal Junction Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":260,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT05836584","title":"Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":240,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06203600","title":"Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":224,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06219941","title":"AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":224,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06662110","title":"IMmune Proteomics to Predict neoAdjuvant Chemotherapy and immunoTherapy Response in Gastric Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":206,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT06814548","title":"Immune Checkpoint Inhibitors (ICIs) Retreatment in Second-line Treatment of Advanced Gastric Cancer: a Retrospective, Real-world Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Yongxu Jia","has_results":false},{"nct_id":"NCT04805307","title":"Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":176,"lead_sponsor_name":"Keymed Biosciences Co.Ltd","has_results":false},{"nct_id":"NCT06028737","title":"Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Ukrainian Society of Clinical Oncology","has_results":false},{"nct_id":"NCT04396821","title":"A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":150,"lead_sponsor_name":"Suzhou Transcenta Therapeutics Co., Ltd.","has_results":false},{"nct_id":"NCT05687357","title":"Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":140,"lead_sponsor_name":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","has_results":false},{"nct_id":"NCT04931654","title":"A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":136,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06047379","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":134,"lead_sponsor_name":"Neonc Technologies, Inc.","has_results":false},{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04492488","title":"A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":129,"lead_sponsor_name":"Shanghai Miracogen Inc.","has_results":false},{"nct_id":"NCT06760858","title":"A Prospective Cohort Study on the Treatment of Locally Advanced Gastric Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":122,"lead_sponsor_name":"Southwest Hospital, China","has_results":false},{"nct_id":"NCT04882241","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT06921928","title":"Study for AZD4360 in Participants With Advanced Solid Tumours","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":117,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04660760","title":"Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":116,"lead_sponsor_name":"Academic and Community Cancer Research United","has_results":false},{"nct_id":"NCT05086692","title":"A Beta-only IL-2 ImmunoTherapY Study","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":115,"lead_sponsor_name":"Medicenna Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06640153","title":"MRI and CT in Gastroesophageal Junction or Upper Gastric Adenocarcinoma","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT04772989","title":"A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Arcus Biosciences, Inc.","has_results":false},{"nct_id":"NCT02572687","title":"A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":85,"lead_sponsor_name":"Eli Lilly and Company","has_results":false},{"nct_id":"NCT04082364","title":"Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":82,"lead_sponsor_name":"MacroGenics","has_results":true},{"nct_id":"NCT05149807","title":"Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":81,"lead_sponsor_name":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT05322577","title":"A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":72,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT07517211","title":"A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer, FAST-GO Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":72,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT04276493","title":"Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":71,"lead_sponsor_name":"BeiGene","has_results":false},{"nct_id":"NCT07115043","title":"A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05894824","title":"T-Dxd in Combination With Ramucirumab as HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":58,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT04208958","title":"Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":56,"lead_sponsor_name":"Vedanta Biosciences, Inc.","has_results":true},{"nct_id":"NCT01743365","title":"Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"Hellenic Cooperative Oncology Group","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}